Brind.

Sage Therapeutics rejected a takeover offer from Biogen, while Supernus Pharmaceuticals aimed to expand its neuropsychiatric portfolio.

4 reports, 4 independent Updated Sep 2
Gone quiet Reached 4 outlets in its first 24 hours
Reports
4
Developments
4
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Sage Therapeutics rejected a takeover offer from Biogen, while Supernus Pharmaceuticals aimed to expand its neuropsychiatric portfolio.

Who's involved

What this event is mainly about
Sage Therapeutics (United States)BiogenSupernus Pharmaceuticals (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.Sub-event
  2. Corporate developments: Sage rejected Biogen's offer; Supernus focused on portfolio expansion.1 source
  3. Sage Therapeutics announced the acquisition of Supernus Pharmaceuticals.1 source
  4. Supernus Pharmaceuticals is acquiring Sage Therapeutics, resolving the earlier strategic alternatives discussion.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeySage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Sage Therapeutics, Inc. is placed
  • Pharmaceutical TechnologySupernus strengthens neuropsychiatric portfolio with Sage Therapeutics Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, Supe
  • Business WireSage Therapeutics Announces Second Quarter 2025 Financial Results Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorde
  • BioPharma DiveSage to lay off most staff amid Supernus buyout This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sage